USE1 Inhibitors
Chemical inhibitors of USE1 can impede the protein's function by targeting various cellular mechanisms involved in vesicular transport. Alsterpaullone operates by inhibiting CDK5/p25 complex, a kinase which indirectly affects USE1's role in the neuronal signaling pathways that oversee vesicular transport through phosphorylation events. Similarly, Roscovitine targets cyclin-dependent kinases (CDKs) that regulate intracellular transport, thus indirectly affecting USE1's function. Gö6976 exerts its action by selectively inhibiting protein kinase C isoforms, which are involved in the regulation of intracellular trafficking, including vesicular fusion and transport processes that USE1 facilitates. Wortmannin's inhibitory effects on phosphoinositide 3-kinases disrupt vesicle formation, impairing USE1's role in this process.
Concurrently, agents that disrupt cytoskeletal components essential for vesicle movement also functionally inhibit USE1. Latrunculin A binds to actin monomers, preventing their polymerization, which is crucial for vesicle motility. Y-27632 inhibits Rho-associated protein kinase, affecting the actin cytoskeleton organization and, consequently, vesicle transport that USE1 is involved in. ML-7, by inhibiting myosin light chain kinase, impedes myosin activation for vesicle movement, thereby affecting USE1 function. Compounds like Nocodazole and Vinblastine disrupt microtubule dynamics, a critical component of the cellular scaffold that supports vesicular trafficking involving USE1, with nocodazole disassembling microtubules and vinblastine preventing their assembly. In contrast, Taxol stabilizes microtubules, which can also affect USE1's role by preventing the dynamic rearrangement of microtubules necessary for vesicular transport. Lastly, Brefeldin A and Thapsigargin target the organelle function and calcium homeostasis, respectively, with Brefeldin A disrupting the Golgi apparatus and Thapsigargin inhibiting the sarco/endoplasmic reticulum Ca2+-ATPase, both leading to conditions that impede USE1's role in vesicle fusion.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone inhibits CDK5/p25 complex, which is indirectly involved in the regulation of USE1 through neuronal signaling pathways. Inhibition of CDK5 activity can inhibit USE1 by limiting phosphorylation events that are necessary for its function in vesicular transport. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts the Golgi apparatus structure and function. USE1 is involved in vesicle transport, and the disruption of Golgi function can inhibit the vesicular transport processes in which USE1 is involved, therefore functionally inhibiting USE1. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $227.00 | 8 | |
Gö6976 is a selective inhibitor of protein kinase C (PKC) isoforms. PKC is involved in the regulation of intracellular trafficking, and inhibiting PKC can disrupt these pathways, leading to the functional inhibition of USE1 in vesicular fusion and transport. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $265.00 $815.00 | 36 | |
Latrunculin A binds to actin monomers and prevents their polymerization. As actin dynamics are crucial for vesicle movement, which is a process that USE1 is known to be involved in, inhibiting actin polymerization can functionally inhibit USE1 by impeding vesicle transport. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
ML-7 inhibits myosin light chain kinase (MLCK), which is essential for myosin activation and subsequent vesicle movement. By inhibiting MLCK, ML-7 can indirectly inhibit USE1 by impairing the cytoskeletal dynamics required for its vesicular transport function. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Nocodazole disrupts microtubule polymerization. USE1 is involved in vesicular trafficking along microtubules, so nocodazole can functionally inhibit USE1 by disrupting the microtubule network required for vesicle transport. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $41.00 $74.00 $221.00 $247.00 $738.00 $1220.00 | 39 | |
Paclitaxel stabilizes microtubules and inhibits their disassembly, which can affect vesicle transport and, consequently, the function of USE1 in vesicle fusion processes by preventing the dynamic rearrangement of microtubules necessary for these processes. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine inhibits cyclin-dependent kinases (CDKs) which are involved in cell cycle regulation and intracellular transport. By inhibiting CDK activity, roscovitine can functionally inhibit USE1 by affecting the cellular pathways that require CDKs for vesicle transport. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin inhibits the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA), leading to a disruption of calcium homeostasis. Calcium is important for vesicle fusion, and thus USE1's role in vesicle fusion can be functionally inhibited by thapsigargin. | ||||||
Vinblastine | 865-21-4 | sc-491749 sc-491749A sc-491749B sc-491749C sc-491749D | 10 mg 50 mg 100 mg 500 mg 1 g | $102.00 $235.00 $459.00 $1749.00 $2958.00 | 4 | |
Vinblastine interferes with microtubule assembly. As USE1 is involved in vesicular trafficking that relies on microtubules, vinblastine can functionally inhibit USE1 by disrupting the microtubule-dependent transport mechanisms. | ||||||